NCCN Prostate Cancer Intermediate Risk Group
specificA prostate cancer risk group characterized by: clinical stage T2b-T2c, biopsy Gleason score 7, or PSA level 10-20 ng/mL.
Top Centers for NCCN Prostate Cancer Intermediate Risk Group
Ranked by research excellence score (trials · grants · publications). Methodology →
No centers currently specializing in this cancer type.
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →